# Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

> **NCT07476170** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 14000 (estimated)

## Conditions studied

- HR+/HER2- Advanced or Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07476170
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 14000 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476170, "Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07476170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*